Islet After Kidney Transplant for Type 1 Diabetes
| Status: | Recruiting |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 5/5/2014 |
| Start Date: | August 2011 |
| End Date: | September 2017 |
| Contact: | Donna Y Winborne, BSN |
| Email: | dwinborne@mcvh-vcu.edu |
| Phone: | 804 828-2463 |
Pancreatic Islet Transplantation in Patients With Type 1 Diabetes Mellitus
The purpose of this study is to determine if prolonged administration of the anti TNF (tumor
necrosis factor)-Alpha agent etanercept is associated with enhanced graft survival in
patients undergoing islet after kidney transplantation.
necrosis factor)-Alpha agent etanercept is associated with enhanced graft survival in
patients undergoing islet after kidney transplantation.
Inclusion Criteria:
- Patients with type 1 diabetes mellitus, who have a stable functioning renal
transplant, are taking the appropriate maintenance immunosuppression and have no
severe health problems that preclude them receiving an islet transplant will be
considered for inclusion.
Exclusion Criteria:
- Have a history of or findings suggestive of unstable diabetic complications (e.g.
active eye disease)
- Active infections (clinically or by laboratory testing)
- History of current malignancy or suspicion of malignancy until properly investigated
and excluded
- Liver or biliary abnormalities
- Unstable cardiovascular disease
- Findings to suggest immunological sensitization or those women who have the potential
to get pregnant and are not using a sufficient method of contraception
We found this trial at
1
site
Click here to add this to my saved trials
